Sequential ICI plus Anti-VEGF/TKI with On-Demand TACE beyond RECIST Progression Improves Pathological Response, Resectability, and Survival in Unresectable HCC
Liver Cancer · 05.03.2026 · 15 (2) · 169-177
DOI: 10.1159/000551332 ↗Kurz gefasst
Editorial in der Zeitschrift Liver Cancer, online erschienen am 05.03.2026. Verfasst von Masatoshi Kudo. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Zitieren
APA
Kudo, M. (2026). Sequential ICI plus Anti-VEGF/TKI with On-Demand TACE beyond RECIST Progression Improves Pathological Response, Resectability, and Survival in Unresectable HCC. Liver Cancer, 15(2), 169-177. https://doi.org/10.1159/000551332
Vancouver
Kudo M. Sequential ICI plus Anti-VEGF/TKI with On-Demand TACE beyond RECIST Progression Improves Pathological Response, Resectability, and Survival in Unresectable HCC. Liver Cancer. 2026;15(2):169-177. doi:10.1159/000551332
BibTeX
@article{Kudo2026,
author = {Kudo, Masatoshi},
title = {Sequential ICI plus Anti-VEGF/TKI with On-Demand TACE beyond RECIST Progression Improves Pathological Response, Resectability, and Survival in Unresectable HCC},
journal = {Liver Cancer},
year = {2026},
volume = {15},
number = {2},
pages = {169--177},
doi = {10.1159/000551332}
}
EUVIMED